| SOXS 1.8134 1.31% | TPET 1.0099 140.45% | ONDS 10.685 6.00% | STAK 0.7273 71.13% | NVDA 182.49 2.99% | TMDE 2.38 158.08% | TURB 1.195 76.93% | BITO 9.53 5.19% | XLE 56.825 1.62% | RYDE 0.3346 44.60% | EONR 0.4951 14.61% | NOK 8.31 7.64% | TZA 6.1006 -2.08% | BHAT 0.039 -21.21% | NVD 7.0729 -6.07% | IBIT 39.235 5.50% | USEG 1.1477 7.26% | TQQQ 49.77 0.50% | PLUG 1.7892 -0.04% | MSTX 2.4874 10.55% | TSLS 5.645 0.09% | AES 14.3 -17.25% | JDST 1.23 6.03% | AAL 12.53 -4.13% | PLTR 146.02 6.44% | BATL 10.45 89.31% | NFLX 97.185 0.98% | HYG 80.345 -0.46% | SQQQ 70.49 -0.51% | TSLL 14.645 -0.37% | QQQ 608.4 0.18% | SOFI 18.145 2.17% | MARA 9.485 6.10% | ETHA 15.38 5.92% | XLF 51.425 -0.01% | INTC 45.0699 -1.18% | NU 15.195 1.44% | IWM 263.25 0.70% | TLT 89.495 -1.46% | TSLA 401.9 -0.15% | BMNR 20.52 8.11% | CRCG 2.9598 23.33% | NIO 4.72 -3.08% | VG 11.12 14.76% | BYND 0.8594 -9.12% | BANL 0.6087 34.82% | BKLN 20.245 0.17% | RCAT 13.7841 18.32% | LQD 110.885 -0.71% | KOS 2.195 -5.79%

Barclays Downgrades Medpace To Underweight, Cites Valuation Concerns

Barclays downgraded Medpace Holdings Inc. (NASDAQ: MEDP) from Equalweight to Underweight and reduced its price target to $425.00 from $450.00.

The firm said the downgrade was primarily valuation-driven, noting that Medpace shares were trading well above the premium historically enjoyed relative to peers. While the biotech market was described as “bouncing along the bottom,” Barclays said it expected the company to continue winning new business.

However, the firm flagged potential risk in the second half of 2026, citing concern over whether Medpace could fill its backlog with faster-burning projects to sustain elevated growth as more traditional work ramps.

Published on: October 2, 2025